| Literature DB >> 23721889 |
Sarah Laraway1, Catherine Breen, Jean Mercer, Simon Jones, James E Wraith.
Abstract
Enzyme replacement therapy is widely used as treatment for mucopolysaccharidosis I (MPS I), and there is evidence that this produces improvement in certain clinical domains. There does appear to be variation in the response of clinical features to treatment once these are established. In a reported sibling pair, when enzyme replacement therapy was commenced pre-symptomatically in the younger child, the natural history of the condition appeared to be affected. We present data from three siblings treated with enzyme replacement therapy at different ages which supports this finding.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23721889 DOI: 10.1016/j.ymgme.2013.04.023
Source DB: PubMed Journal: Mol Genet Metab ISSN: 1096-7192 Impact factor: 4.797